Little is known about TP53 mutations and their association with adverse prognosis and chemotherapy resistance in chronic lymphocytic leukemia (CLL). Here, Florence Cymbalista, MD, of Avicenne Hospital, Bobigny, France, discusses the retrospective analysis of CLL patients with TP3 mutations from the French Innovative Leukemia Organization (FILO) Group. She highlights the need for further investigation and the importance of databases of genetic mutations. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,
TP53 mutations in CLL: a large retrospective analysis
